Champions Oncology, Inc. (FRA:2I3)

Market Cap	58.67M -29.6%
Revenue (ttm)	50.65M +4.4%
Net Income	-1.00M
EPS	-0.07
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	170
Open	4.200
Previous Close	4.160
Day's Range	4.140 - 4.200
52-Week Range	4.060 - 6.750
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Jul 27, 2026

About Champions Oncology

Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States. The company provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice through TumorGraft Technology Platform. It also offers translational oncology solutions that utilizes its technology platform to provide research services that assist in the drug development process of pharmaceutical and biotechnology companies. In addition, the company offers Lumin...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1985
• Employees: 214
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 2I3

Financial Performance

Financial numbers in USD

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 27, 2026

Data Sources Report a data error